Venus Remedies Ltd. (BSE: 526953) is a Panchkula, Haryana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,195 Cr, it ranks #1,196 by market cap among the 6,137 Indian listed companies on FinBizNet, and #38 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,404.30 (as of 25 Oct 2026), the share price is 31.3% below its 52-week high of ₹2,044.30 and 223.3% above its 52-week low of ₹434.35. The share price is up 204.3% over one year and down 14.8% over three months.
| Current Price | ₹1,404.30 |
|---|---|
| Market Cap | ₹2,195 Cr |
| BSE Code | 526953 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 20.7 |
| Return on Equity | 16.78% |
| Return on Assets | 9.87% |
| 52-Week Range | ₹434.35 – ₹2,044.30 |
| 1-Year Price Change | +204.3% |
| 3-Month Price Change | -14.8% |
| Beta (1Y) | -0.27 |
| Dividend Yield | 0.63% |
| Headquarters | Panchkula, Haryana |
| Website | www.venusremedies.com |
| Revenue | ₹179 Cr |
|---|---|
| Net Profit | ₹23 Cr |
| Net Margin | 12.8% |
| EPS (Basic) | ₹17.18 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.
1. Pharmaceutical Formulation-This segment manufactures and trades in medicines. It offers anti-cancer, anti-infective, neurology, emergency care medicine, skin and wound care, and pain management products.
1. Pharmaceutical Fomulation-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Venus Remedies Ltd. | ₹2,195 Cr | 20.7 | 16.78% | ₹179 Cr | +204.3% |
Listed by market capitalisation. Ratios are shown for context only.
Venus Remedies Ltd. is trading at ₹1,404.30, with a market capitalisation of ₹2,195 Cr.
Venus Remedies Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Venus Remedies Ltd. has a P/E of 20.7 and a return on equity of 16.78%.
Venus Remedies Ltd. is listed on the BSE under the scrip code 526953.
Venus Remedies Ltd.'s share price is up 204.3% over one year and down 14.8% over three months. Its 52-week range is ₹434.35 to ₹2,044.30.
In Q1 FY27, Venus Remedies Ltd. reported revenue of ₹179 Cr and net profit of ₹23 Cr, with basic EPS of ₹17.18 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.